MedTrace Logo

Molecular Characterization for Understanding Biliary Atresia

NCT04272515 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-06-04

No results posted yet for this study

Summary

Although considered a rare disease, Biliary Atresia (BA) is the leading cause of neonatal cholestasis and liver transplantation in children. Little is known about the molecular mechanisms that drive BA. The purpose of this study is to collect the fluid samples, explanted liver tissue samples and dermal biopsy samples to enable investigators to perform the genetic and molecular analyses that might point to the gene(s) and cellular pathway involved in etiology of BA disease.

Conditions

  • Biliary Atresia

Interventions

OTHER

blood sampling

collection of blood sample for preparation of DNA

OTHER

skin biopsy sampling

preparation of primary cultures of dermal fibroblasts from skin biopsy sample

OTHER

explanted liver of BA patients sampling

cryoconservation of liver tissue for molecular analyses

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-07
Primary Completion
2026-02-07
Completion
2032-02-07

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04272515 on ClinicalTrials.gov